ArticleJournal of cachexia, sarcopenia and muscle2025
Ageing Signatures and Disturbed Muscle Regeneration in Muscle Proteome of Inclusion Body Myositis.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Spatial protein expression patterns across pathologically-associated fibers revealed molecular specialization in inclusion body myositis.Cell communication and signaling : CCS · 2026Article
- Ageing-Associated Dysregulation of Myogenic Differentiation in Inclusion Body Myositis.Journal of cachexia, sarcopenia and muscle · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundInclusion body myositis (IBM) is the most common acquired myopathy in adults over the age of 50 years, characterised by inflammatory and degenerative features that lead to progressive muscle weakness and physical disability for lack of effective therapies. The complex interplay between inflammatory and degenerative processes, occurring seemingly simultaneously, presents a challenge to systematically dissect disease pathology and discover novel therapeutic targets.
methodsTo identify proteomic IBM disease signatures and upstream regulators of disease processes in an unbiased manner, we performed high-resolution iTRAQ-labelled mass spectrometry on whole muscle lysates of 28 IBM patients and 28 control individuals. Validation experiments were carried out by conducting immunohistochemical (IHC) stainings on KDM5A and myogenin using control and IBM patient muscle tissue sections. Human myoblasts were used to study involvement of KDM5A, a selected candidate-upstream regulator, in IBM pathomechanisms in vitro.
resultsA total of 627 significantly differentially expressed proteins were found in IBM patients compared to control individuals. The proteomics dataset strongly reflected inflammatory signatures, dysregulations in cellular energy metabolism and altered myogenesis in IBM muscle. Identification of upstream regulators of IBM pathology yielded KDM5A as the top activated and RB1 as the top inhibited upstream regulator. KDM5A, a histone demethylase involved in transcription regulation and (myogenic) differentiation, interacts with RB1 and interconnects core IBM disease signatures in patient muscle tissue. IHC stainings on muscle tissue showed increased presence of myogenin-positive myonuclei (p < 0.0001). KDM5A levels were increased in these myogenin-positive myonuclei in IBM patient muscle tissue compared to healthy controls (p < 0.0001). In vitro differentiation of myoblasts showed gradual KDM5A downregulation throughout myogenic differentiation, confirming presence in immature myoblasts and low levels in more mature myotubes. Proof-of-concept pharmacological inhibition of KDM5A with ryuvidine showed a significant effect on amyloid precursor protein (APP) abundance (p = 0.0003) and aggregation (p = 0.0132) in a conditional IBM-mimicking inflammatory model.
conclusionsThis unbiased proteomics study reflects known core features of IBM pathomechanisms while simultaneously providing novel insights into the proteomic landscape of IBM, most notably dysregulation of metabolic pathways and failure of myogenesis. The identification and exploration of KDM5A as a potential upstream driver of disease pathology could interconnect failure of myogenic differentiation with (known) disease processes in IBM and provides a target for future study and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.